雾化吸入布地奈德治疗重度慢性阻塞性肺疾病急性加重中的作用  

Nebulized Budesonide in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

作　　者：李燕舞[1] 徐治波[1] 包勇[1] 高蜀生[1] 

机构地区：[1]成都市第三人民医院,四川成都610031

出　　处：《华西医学》2008年第3期519-520,共2页West China Medical Journal

摘　　要：目的:评价布地奈德雾化治疗重度慢性阻塞性肺疾病急性加重期患者的临床应用价值。方法:选择重度COPD急性加重期患者150例随机分3组,布地奈德组给予布地奈德雾化液2mg雾化吸入,每8h1次;注射甲基强的松龙组给予甲基强的松龙40mg静脉推注,每天1次;对照组不使用任何糖皮质激素。观察期为48h、7d。结果:布地奈德组、甲基强的松龙组和对照组比较,FEV1、PaO2、PaCO2改善值具有显著性差异(P<0·05);布地奈德组、甲基强的松龙组两组各项指标改善程度相似(P>0·05),但布地奈德组副作用明显低于甲基强的松龙组(P<0·05)。结论:雾化布地奈德混悬液可有效改善AECOPD的气流受限,疗效与注射甲基强的松龙相似,全身副作用小,可作为皮质激素治疗的另一种选择。Objective：To evaluate the clinical efficacy of nebulized budesonide （NB） in acute exacerbations of chronic obstructive pulmonary disease （COPD）.Methods：Patients were randomly divided into three groups.The NS group received nebulized budesonide by exacerbation with 2mg every 8h.The prednisolone group was treated with 40mg by intravenous every day.The placebo was offered common treatment and not treated with adrenocortical hormones.All groups were observed for 48h and 7d.Results：Both budesonide and prednisolone improved in FEV1、PaO2 and PaCO2 wwhen compared with placebo（P〈0.05）.The difference in FEV1、PaO2、 PaCO2 between budesonide and prednisolone was not significant（P〉0.05）.The occurrence of serious adverse in the NS group were lower than the PS group（P〈0.05）.Conclusion：Both budesonide and prednisolone improved obstruent airflow in COPD patients Nebulized budesonide may be an alternative to intravenous prednisolone in the treatment of nonacidotic exacerbations of COPD with lower adverse events.

关 键 词：慢性阻塞性肺疾病 布地奈德混悬液 吸入 甲基强的松龙 

分 类 号：R563.9[医药卫生—呼吸系统]